Physician profile

Nechama Bernhardt

Neurology (Psychiatry & Neurology) · Towson, MD

NPI 1225038128

$289.61

in general payments reported to CMS, 2019-2025

11 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$24.63

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Assertio Therapeutics, INC. $42.46 2019
Alnylam Pharmaceuticals INC. $31.50 2019
Upsher-Smith Laboratories LLC $29.82 2019
Alexion Pharmaceuticals, INC. $29.24 2019
Ucb, INC. $28.16 2019
Lilly USA, LLC $27.91 2019
Abbvie INC. $24.63 2023 Botox
Novartis Pharmaceuticals Corporation $23.70 2019
Eisai INC. $22.21 2019
Biogen, INC. $17.38 2019
Checkpoint Surgical, INC $12.60 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Nechama Bernhardt

$289.61

in general payments reported 2019-2025

Years
2019-2023
Top company
Assertio Therapeutics, INC.

https://glasscript.com/doctor/853277/nechama-bernhardt

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.